Penumbra, Inc. $PEN Shares Bought by Intech Investment Management LLC

Intech Investment Management LLC lifted its holdings in Penumbra, Inc. (NYSE:PEN) by 13.3% during the 3rd quarter, HoldingsChannel.com reports. The firm owned 48,971 shares of the company’s stock after acquiring an additional 5,749 shares during the quarter. Intech Investment Management LLC’s holdings in Penumbra were worth $12,405,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also made changes to their positions in PEN. Invesco Ltd. boosted its holdings in Penumbra by 1,139.3% during the second quarter. Invesco Ltd. now owns 633,485 shares of the company’s stock worth $162,571,000 after buying an additional 582,369 shares in the last quarter. Norges Bank acquired a new stake in shares of Penumbra during the 2nd quarter valued at $114,014,000. Qube Research & Technologies Ltd bought a new stake in shares of Penumbra during the 2nd quarter worth $53,818,000. Man Group plc boosted its stake in shares of Penumbra by 1,862.2% during the 2nd quarter. Man Group plc now owns 206,461 shares of the company’s stock worth $52,984,000 after acquiring an additional 195,939 shares in the last quarter. Finally, AQR Capital Management LLC grew its holdings in shares of Penumbra by 139.4% in the 2nd quarter. AQR Capital Management LLC now owns 330,990 shares of the company’s stock worth $84,939,000 after acquiring an additional 192,734 shares during the last quarter. 88.88% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

Several equities research analysts have recently commented on PEN shares. BTIG Research downgraded Penumbra from a “buy” rating to a “neutral” rating and set a $349.00 target price for the company. in a report on Thursday, January 15th. Weiss Ratings restated a “hold (c)” rating on shares of Penumbra in a report on Monday, December 29th. Wells Fargo & Company reaffirmed an “equal weight” rating and set a $374.00 price objective on shares of Penumbra in a research note on Thursday, January 15th. UBS Group reiterated a “neutral” rating and issued a $374.00 target price on shares of Penumbra in a report on Thursday. Finally, Wall Street Zen downgraded shares of Penumbra from a “buy” rating to a “hold” rating in a research report on Saturday, January 17th. Four equities research analysts have rated the stock with a Buy rating and fourteen have assigned a Hold rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of “Hold” and an average target price of $361.69.

Penumbra News Roundup

Here are the key news stories impacting Penumbra this week:

• Positive Sentiment: Q4 results beat consensus: Penumbra reported $1.18 EPS vs. $1.12 expected and revenue of $385.4M vs. $367.2M est., with revenue up ~22% year‑over‑year and healthy margins/ROE — a clear near‑term fundamental catalyst supporting the rally. Penumbra Q4 and FY2025 Results
• Positive Sentiment: Analyst/coverage writeups emphasize the beat and bullish tone on the quarter — additional media amplification likely amplified buying interest. Penumbra Reports Bullish Q4
• Positive Sentiment: Product pipeline expansion: a new class of coils for treating pelvic venous disease highlights incremental TAM expansion beyond core thrombectomy products, supporting longer‑term growth expectations. New Coils for Pelvic Venous Disease
• Neutral Sentiment: Intraday trading halt: PEN was temporarily halted for “News pending” around the quarter release — standard procedure that can exaggerate volatility but not a directional signal by itself.
• Negative Sentiment: Street sentiment mixed: coverage aggregate shows an average analyst rating of “Hold,” which may limit upside if analyst revisions aren’t strongly positive post‑print. Analyst Ratings Summary
• Negative Sentiment: Valuation considerations: PEN trades at a high P/E (~75x) vs. growth expectations — strong results help justify the multiple, but elevated valuation makes the stock sensitive to any slowdown or weaker guidance.

Insider Activity at Penumbra

In other news, Director Arani Bose sold 15,000 shares of the business’s stock in a transaction on Thursday, December 11th. The shares were sold at an average price of $308.82, for a total transaction of $4,632,300.00. Following the transaction, the director directly owned 258,462 shares in the company, valued at $79,818,234.84. The trade was a 5.49% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, Director Harpreet Grewal sold 186 shares of the company’s stock in a transaction on Tuesday, January 6th. The stock was sold at an average price of $312.64, for a total transaction of $58,151.04. Following the completion of the transaction, the director directly owned 8,230 shares in the company, valued at $2,573,027.20. This trade represents a 2.21% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last 90 days, insiders sold 16,372 shares of company stock worth $5,044,546. Corporate insiders own 4.20% of the company’s stock.

Penumbra Trading Up 0.9%

NYSE:PEN opened at $341.87 on Friday. The company has a debt-to-equity ratio of 0.02, a current ratio of 6.73 and a quick ratio of 4.18. Penumbra, Inc. has a fifty-two week low of $221.26 and a fifty-two week high of $362.41. The stock’s 50-day moving average is $335.06 and its two-hundred day moving average is $291.12. The stock has a market cap of $13.39 billion, a PE ratio of 75.64, a price-to-earnings-growth ratio of 2.08 and a beta of 0.82.

Penumbra (NYSE:PEN) last posted its quarterly earnings results on Tuesday, March 3rd. The company reported $1.18 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.12 by $0.06. Penumbra had a net margin of 12.66% and a return on equity of 11.72%. The business had revenue of $385.39 million during the quarter, compared to analyst estimates of $367.18 million. During the same period in the prior year, the firm earned $0.97 earnings per share. The firm’s revenue was up 22.2% compared to the same quarter last year. As a group, equities research analysts forecast that Penumbra, Inc. will post 3.67 earnings per share for the current fiscal year.

About Penumbra

Penumbra, Inc is a global healthcare company specializing in the development and manufacture of innovative medical devices that address neurovascular and peripheral vascular conditions. The company focuses on products designed to improve patient outcomes in acute ischemic stroke, aneurysm treatment and peripheral thrombectomy. Penumbra’s technologies are used by interventional neuroradiologists, neurosurgeons and interventional cardiologists in hospitals and clinics around the world.

At the core of Penumbra’s portfolio is its mechanical thrombectomy platform, which includes aspiration catheters and accessory devices engineered to remove blood clots in acute stroke cases.